Ocular nonsteroidal inflammatory drugs: where do we stand today?

References

• Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007;42:3–27.
   PubMedGoogle Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108–133.
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s–110s.
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–235.
   PubMedGoogle Scholar
• Bacchi S, Palumbo P, Sponta A, et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Aiaamc 2012;11:52–64.
   Google Scholar
• Hanna VS, Hafez E. Synopsis of arachidonic acid metabolism: a review. J Adv Res 2018;11:23–32.
   PubMed Web of Science ®Google Scholar
• Poorani R, Bhatt AN, Dwarakanath BS, et al. COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance. Eur J Pharmacol 2016;785:116–132.
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387–437.
   PubMed Web of Science ®Google Scholar
• Doucette LP, Walter MA. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthalmic Genet 2017;38:108–116.
   PubMed Web of Science ®Google Scholar
• Bhattacherjee P. Prostaglandins and inflammatory reactions in the eye. Methods Find Exp Clin Pharmacol 1980;2:17–31.
   PubMedGoogle Scholar
• Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001;42:2338–2346.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003;458:283–289.
   PubMed Web of Science ®Google Scholar
• Cheng T, Cao W, Wen R, et al. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci 1998;39:581–591.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–442.
   PubMed Web of Science ®Google Scholar
• Wilson DJ, Schutte SM, Abel SR. Comparing the efficacy of ophthalmic NSAIDs in common indications: a literature review to support cost-effective prescribing. Ann Pharmacother 2015;49:727–734.
   PubMed Web of Science ®Google Scholar
• Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1–11.
   PubMedGoogle Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217:89–98.
   PubMed Web of Science ®Google Scholar
• Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007;33:1539–1545.
   PubMed Web of Science ®Google Scholar
• Ellis PP, Pfoff DS, Bloedow DC, et al. Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol 1994;10:677–682.
   PubMedGoogle Scholar
• Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina (Philadelphia) 2009;29:1310–1313.
   PubMed Web of Science ®Google Scholar
• Currie GM. Pharmacology, part 1: introduction to pharmacology and pharmacodynamics. J Nucl Med Technol 2018;46:81–86.
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J 2008;10:229–241.
   PubMed Web of Science ®Google Scholar
• Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006;22:1133–1140.
   PubMed Web of Science ®Google Scholar
• Kraff MC, Martin RG, Neumann AC, et al. Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cataract Refract Surg 1994;20:138–144.
   PubMed Web of Science ®Google Scholar
• Maier TJ, Tausch L, Hoernig M, et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008;76:862–872.
   PubMed Web of Science ®Google Scholar
• Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012;96:614–618.
   PubMed Web of Science ®Google Scholar
• Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004;122:487–494.
   PubMed Web of Science ®Google Scholar
• Hoffman RS, Braga-Mele R, Donaldson K, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 2016;42:1368–1379.
   PubMed Web of Science ®Google Scholar
• Brandsdorfer A, Patel SH, Chuck RS. The role of perioperative nonsteroidal anti-inflammatory drugs use in cataract surgery. Curr Opin Ophthalmol 2019;30:44–49.
   PubMed Web of Science ®Google Scholar
• Roberts CW. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 1996;103:636–639.
   PubMed Web of Science ®Google Scholar
• Medic A, Jukic T, Matas A, et al. Effect of preoperative topical diclofenac on intraocular interleukin-12 concentration and macular edema after cataract surgery in patients with diabetic retinopathy: a randomized controlled trial. Croat Med J 2017;58:49–55.
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Whitaker JS, Jackson MA, et al. Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. J Cataract Refract Surg 2017;43:597–605.
   PubMed Web of Science ®Google Scholar
• Juthani VV, Clearfield E, Chuck RS. Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database Syst Rev 2017;7:CD010516.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xia S, Wang E, et al. Comparison of the efficacy and patients’ tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: a meta-analysis of randomized controlled trials. PLoS One 2017;12:e0173254.
   PubMed Web of Science ®Google Scholar
• Vote B, Fuller JR, Bevin TH, et al. Systemic anti-inflammatory fibrosis suppression in threatened trabeculectomy failure. Clin Exp Ophthalmol 2004;32:81–86.
   PubMed Web of Science ®Google Scholar
• Almatlouh A, Bach-Holm D, Kessel L. Steroids and nonsteroidal anti-inflammatory drugs in the postoperative regime after trabeculectomy – which provides the better outcome? A systematic review and meta-analysis. Acta Ophthalmol 2019;97:146–157.
   PubMed Web of Science ®Google Scholar
• Fan DS, Ng JS, Lam DS. A prospective study on ocular hypertensive and antiinflammatory response to different dosages of fluorometholone in children. Ophthalmology 2001;108:1973–1977.
   PubMed Web of Science ®Google Scholar
• Yang HK, Han SB, Hwang JM. Diclofenac versus fluorometholone after strabismus surgery in children. Br J Ophthalmol 2014;98:734–738.
   PubMed Web of Science ®Google Scholar
• Snir M, Axer-Siegel R, Friling R, et al. Efficacy of diclofenac versus dexamethasone for treatment after strabismus surgery. Ophthalmology 2000;107:1884–1888.
   PubMed Web of Science ®Google Scholar
• Kim J, Choi DC, Bae S, et al. A randomized clinical trial of topical diclofenac, fluorometholone, and dexamethasone for control of inflammation after strabismus surgery. J Ocul Pharmacol Ther 2018;34:550–554.
   PubMed Web of Science ®Google Scholar
• Naithani P, Puranik S, Vashisht N, et al. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery. Retina (Philadelphia) 2012;32:250–255.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lo WR, Hubbard GB, 3rd, et al. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Arch Ophthalmol 2008;126:1203–1208.
   PubMedGoogle Scholar
• Mirshahi A, Djalilian A, Rafiee F, et al. Topical administration of diclofenac (1%) in the prevention of miosis during vitrectomy. Retina (Philadelphia) 2008;28:1215–1220.
   PubMed Web of Science ®Google Scholar
• Yee RW. Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group. Am J Ophthalmol 1998;125:472–480.
   PubMed Web of Science ®Google Scholar
• Eiferman RA, Hoffman RS, Sher NA. Topical diclofenac reduces pain following photorefractive keratectomy. Arch Ophthalmol 1993;111:1022.
   PubMedGoogle Scholar
• Durrie DS, Kennard MG, Boghossian AJ. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). Adv Therapy 2007;24:1278–1285.
   PubMed Web of Science ®Google Scholar
• Razmju H, Khalilian A, Peyman A, et al. Preoperative topical diclofenac and ketorolac in prevention of pain and discomfort following photorefractive keratectomy: a randomized double-masked placebo-controlled clinical trial. Int J Prev Med 2012;3:S199–S206.
   PubMedGoogle Scholar
• Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998;96:557–634.
   PubMedGoogle Scholar
• Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology 2016;123:316–323.
   PubMed Web of Science ®Google Scholar
• Schmier JK, Covert DW, Hulme-Lowe CK, et al. Treatment costs of cystoid macular edema among patients following cataract surgery. Clin Ophthalmol 2016;10:477–483.
   PubMed Web of Science ®Google Scholar
• Olson RJ, Braga-Mele R, Chen SH, et al. Cataract in the adult eye preferred practice pattern(R). Ophthalmology 2017;124:P1–P119.
   PubMed Web of Science ®Google Scholar
• Lim BX, Lim CH, Lim DK, et al. Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery. Cochrane Database Syst Rev 2016;11:CD006683.
   PubMed Web of Science ®Google Scholar
• Kessel L, Tendal B, Jorgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology 2014;121:1915–1924.
   PubMed Web of Science ®Google Scholar
• Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008;146:554–560.
   PubMed Web of Science ®Google Scholar
• Wielders LH, Lambermont VA, Schouten JS, et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis. Am J Ophthalmol 2015;160:968–981 e33.
   PubMed Web of Science ®Google Scholar
• Lee TH, Choi W, Ji YS, et al. Comparison of ketorolac 0.45% versus diclofenac 0.1% for macular thickness and volume after uncomplicated cataract surgery. Acta Ophthalmol 2016;94:e177–82.
   PubMed Web of Science ®Google Scholar
• Wielders LH, Schouten JS, Aberle MR, et al. Treatment of cystoid macular edema after cataract surgery. J Cataract Refract Surg 2017;43:276–284.
   PubMed Web of Science ®Google Scholar
• Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034–2038.
   PubMed Web of Science ®Google Scholar
• Singal N, Hopkins J. Pseudophakic cystoid macular edema: ketorolac alone vs. ketorolac plus prednisolone. Can J Ophthalmol 2004;39:245–250.
   PubMed Web of Science ®Google Scholar
• Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina (Philadelphia) 2010;30:260–266.
   PubMed Web of Science ®Google Scholar
• Faghihi H, Yahyapour H, Mahmoudzadeh R, et al. Comparison of intravitreal bevacizumab and intravitreal diclofenac in the treatment of diabetic macular edema: a 6-month follow-up. Med Hypothesis Discov Innov Ophthalmol 2017;6:67–75.
   PubMedGoogle Scholar
• Kianersi F, Rezaeian-Ramsheh A, Pourazizi M, et al. Intravitreal diclofenac for treatment of refractory uveitis-associated cystoid macular oedema: A before and after clinical study. Acta Ophthalmol 2018;96:e355–e360.
   PubMed Web of Science ®Google Scholar
• van Kooij B, De Boer J, Ten Dam N, et al. The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edema. Am J Ophthalmol 2005;140:563–564.
   PubMed Web of Science ®Google Scholar
• Grob SR, Gonzalez-Gonzalez LA, Daly MK. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Clin Ophthalmol 2014;8:1281–1289.
   PubMedGoogle Scholar
• Sanchez-Hernandez MC, Montero J, Rondon C, et al. Consensus document on allergic conjunctivitis (DECA). J Investig Allergol Clin Immunol 2015;25:94–106.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Castegnaro A, Valerio AL, et al. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol 2015;15:482–488.
   PubMed Web of Science ®Google Scholar
• Keane-Myers A. The pathogenesis of allergic conjunctivitis. Curr Allergy Asthma Rep 2001;1:550–557.
   PubMedGoogle Scholar
• Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38:141–148.
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38:133–140.
   PubMed Web of Science ®Google Scholar
• Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998;14:137–145.
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Koester J, Schaich L, et al. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1995;11:361–368.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Cancarini A, et al. Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. Diabetes Metab 2019;45:517–527.
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam 2013;2013:281981.
   PubMedGoogle Scholar
• Schoenberger SD, Kim SJ, Sheng J, et al. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci 2012;53:5906–5911.
   PubMed Web of Science ®Google Scholar
• Powell ED, Field RA. Diabetic retinopathy and rheumatoid arthritis. Lancet 1964;2:17–18.
   PubMed Web of Science ®Google Scholar
• Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes 1989;38:491–498.
   PubMed Web of Science ®Google Scholar
• Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS Report Number 7. Ophthalmology 1991;98:741–756.
   PubMed Web of Science ®Google Scholar
• Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina 2010;30:459–467.
   PubMedGoogle Scholar
• Russo A, Morescalchi F, Vezzoli S, et al. Reduction of vitreous prostaglandin E2 levels after topical administration of indomethacin 0.5%, bromfenac 0.09%, and nepafenac 0.1. Retina (Philadelphia) 2016;36:1227–1231.
   PubMed Web of Science ®Google Scholar
• Pinna A, Blasetti F, Ricci GD, et al. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol 2017;27:326–330.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration. Lancet 2018;392:1147–1159.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Toma HS, Barnett JM, et al. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res 2010;91:537–543.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch Ophthalmol 2010;128:596–600.
   PubMedGoogle Scholar
• Rezaei KA, Toma HS, Cai J, et al. Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice. Invest Ophthalmol Vis Sci 2011;52:701–707.
   PubMed Web of Science ®Google Scholar
• Pekel G, Pekel E. The relationship between nonsteroidal anti-inflammatory drug use and age-related macular degeneration. Am J Ophthalmol 2018;189:176.
   PubMed Web of Science ®Google Scholar
• Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137:615–624.
   PubMed Web of Science ®Google Scholar
• Zweifel SA, Engelbert M, Khan S, et al. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina (Philadelphia) 2009;29:1527–1531.
   PubMed Web of Science ®Google Scholar
• Gomi F, Sawa M, Tsujikawa M, et al. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina (Philadelphia) 2012;32:1804–1810.
   PubMed Web of Science ®Google Scholar
• Chen E, Benz MS, Fish RH, et al. Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol 2010;4:1249–1252.
   PubMedGoogle Scholar
• Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol 2016;30:304–315.
   PubMed Web of Science ®Google Scholar
• Barry RJ, Nguyen QD, Lee RW, et al. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol 2014;8:1891–1911.
   PubMedGoogle Scholar
• Dunne JA, Jacobs N, Morrison A, et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol 1985;69:120–125.
   PubMed Web of Science ®Google Scholar
• Young BJ, Cunningham WF, Akingbehin T. Double-masked controlled clinical trial of 5% tolmetin versus 0.5% prednisolone versus 0.9% saline in acute endogenous nongranulomatous anterior uveitis. Br J Ophthalmol 1982;66:389–391.
   PubMed Web of Science ®Google Scholar
• Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm 2010;18:116–120.
   PubMed Web of Science ®Google Scholar
• Williams CP, Browning AC, Sleep TJ, et al. A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. Eye (Lond) 2005;19:739–742.
   PubMed Web of Science ®Google Scholar
• Daniel Diaz J, Sobol EK, Gritz DC. Treatment and management of scleral disorders. Surv Ophthalmol 2016;61:702–717.
   PubMed Web of Science ®Google Scholar
• Stem MS, Todorich B, Faia LJ. Ocular Pharmacology for Scleritis: Review of Treatment and a Practical Perspective. J Ocul Pharmacol Ther 2017;33:240–246.
   PubMed Web of Science ®Google Scholar
• Beardsley RM, Suhler EB, Rosenbaum JT, et al. Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother 2013;14:411–424.
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Scleritis therapy. Ophthalmology 2012;119:51–58.
   PubMed Web of Science ®Google Scholar
• Bauer AM, Fiehn C, Becker MD. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol 2005;139:1086–1089.
   PubMed Web of Science ®Google Scholar
• de Fidelix TS, Vieira LA, de Freitas D, et al. Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol 2015;35:903–912.
   PubMed Web of Science ®Google Scholar
• Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002;25:233–250.
   PubMed Web of Science ®Google Scholar
• Rigas B, Huang W, Honkanen R. NSAID-induced corneal melt: clinical importance, pathogenesis, and risk mitigation. Surv Ophthalmol 2020;65:1–11.
   PubMed Web of Science ®Google Scholar